CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 205-207

  Estrela, R C E ^a   Santoro, A B ^a   Barroso, P F ^b   Tuyama, M ^b   Suarez Kurtz, G ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BRAZIL; CONCENTRATION (PARAMETERS); CYP3A5 GENE; DNA STRAND; DRUG DISPOSITION; GENE; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PLASMA TROUGH CONCENTRATION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TANZANIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CYTOCHROME P-450 CYP3A; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PYRIMIDINONES; RITONAVIR;

EID: 49149099280     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.12     Document Type: Article

References (12)

1. Vergara, T.R., Estrela, R.C., Suarez-Kurtz, G., Schechter, M., Cerbino-Neto, J. & Barroso, P.F. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Ther. Drug Monit. 28, 175-179 (2006).
2. Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger G. & Lacarelle, B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency. Antimicrob. Agents Chemother. 47, 238-243 (2003).
3. Crommentuyn, K.M. et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br. J. Clin. Pharmacol. 60, 378-389 (2007).
4. Mirghani, R.A. et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genomics 16, 637-645 (2006).
5. Josephson, F. et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81, 708-712 (2007).
6. Sham, H.L. et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42, 3218-3224 (1998).
7. Granfors, M.T., Wang, J.S., Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98, 79-85 (2006).
8. Ernest, C.S. II, Hall, S.D. & Jones, D.R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312, 583-591 (2005).
9. Thompson, E.E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B.A. & Di Rienzo, A. CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059-1069 (2004).
10. Suarez-Kurtz, G., Perini, J.A., Bastos-Rodrigues, L., Pena, S.D.J. & Struchiner, C.J. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8, 1299-1306 (2007).
11. Suarez-Kurtz, G. & Pena, S.D.J. Pharmacogenetics in the Brazilian population. In Pharmacogenomics in Admixed Populations (ed. Suarez-Kurtz, G.) 75-98 (Landes Bioscience, Austin, 2007).
12. Liu, T.C., Lin, S.F., Chen, T.P. & Chang, J.G. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol. Rep. 9, 327-329 (2002).